Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
DUBLIN, Ireland, Dec. 08, 2016 -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will participate in the following conference in December:
The BMO Prescriptions for Success Healthcare Conference
- Date: December 14, 2016
- Presentation Time: 1:00 p.m. EST
- The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com, a replay of the webcast will also be available.
- Location: New York, NY
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
